CAJ | 학술논문

近来关于嵌合抗原受体( chimeric antigen receptor，CAR)修饰T细胞在治疗包括淋巴瘤、白血病、脑胶质瘤、黑色素瘤、肺癌、前列腺癌、胰腺癌及卵巢癌等肿瘤所取得成绩令人振奋。 CAR是利用基因工程将能够与肿瘤抗原结合的受体与跨细胞膜的部分和细胞内信号转导的部分结合起来形成的一种新型受体，它可脱离主要组织相容性复合体的限制单独执行杀伤细胞的功能。 CAR修饰T细胞因其独特的设计和强效的抗肿瘤作用受到人们的追捧。作者就CAR修饰T细胞在临床治疗中的应用、遇到的问题和对应策略作一综述。
근래관우감합항원수체( chimeric antigen receptor，CAR)수식T세포재치료포괄림파류、백혈병、뇌효질류、흑색소류、폐암、전렬선암、이선암급란소암등종류소취득성적령인진강。 CAR시이용기인공정장능구여종류항원결합적수체여과세포막적부분화세포내신호전도적부분결합기래형성적일충신형수체，타가탈리주요조직상용성복합체적한제단독집행살상세포적공능。 CAR수식T세포인기독특적설계화강효적항종류작용수도인문적추봉。작자취CAR수식T세포재림상치료중적응용、우도적문제화대응책략작일종술。
Recently,application of chimeric antigen receptor ( CAR) modified T cells in the treatment of lymphoma, leukemia, brain glioma, melanoma, lung cancer, prostate cancer, panc￣reatic cancer and ovarian cancer has made very exciting progress. CAR is a kind of genetically engi￣neered receptor,the common form of these molecules consists of extracellular antigen recognition re￣gion,spacer,transmembrane domain ( TM ) and intracellular endodomain, the antigen recognition region generally is single￣chain variable fragments ( scFv) derived from monoclonal antibodies which can recognize target antigen without MHC restriction, and the intracellular endodomain generally is comprised of CD3 zeta and co￣stimulating molecules. This kind of unique design and strong anti￣tumor effect make the CAR￣T more and more widely used. In this review, we highlight recent ad￣vances of CAR￣T in clinical applications, discovered problems and possible solving strategies in cancer therapy.